Cymbalta Receives European Approval For The Treatment Of Generalised Anxiety Disorder Eli Lilly and Co (NYSE: LLY) and Boehringer Ingelheim have announced that the European Commission has approved the use of Cymbalta(R) (duloxetine) for the treatment of Generalised Anxiety Disorder (GAD). This approval -- the fourth for duloxetine in Europe -- was issued on 28 July following an initial positive opinion issued by the European
Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) on 26 June 2008.
Source: www.medicalnewstoday.comHuman Genome Sciences Completes Enrollment In Randomized Phase 2 Trial Of HGS-ETR1 In Non-Small Cell Lung Cancer Human Genome Sciences, Inc. (Nasdaq: HGSI) announced that it has completed the enrollment and initial dosing of patients in a randomized Phase 2 trial of HGS-ETR1 (mapatumumab) in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC).
Source: www.medicalnewstoday.comIndevus Pharmaceuticals Announces Completion Of Enrollment In Phase III Trial Of PRO 2000 Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) announced the completion of enrollment in Protocol MDP 301, a Phase III clinical trial of PRO 2000, the Company's candidate vaginal microbicide for the prevention of HIV and other sexually transmitted infections.
Source: www.medicalnewstoday.com
# posted by Network @ 6:00 AM
